It has been a busy week for psychedelic medicines developer Cybin, marked by a breakthrough designation (BTD) from the FDA for its depression therapy, new clinical data, a
Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.
A small clinical trial has provided the first evidence that the psychedelic medicine psilocybin may have a role to play in the treatment of anorexia nervosa, an eating dis
Psilocybin, a psychedelic compound found in certain mushrooms, could offer a more cost-effective treatment option for major depressive disorder than current methods, according to rese
Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo